The Role of ADAM17 in Inflammation-Related Atherosclerosis

J Cardiovasc Transl Res. 2022 Dec;15(6):1283-1296. doi: 10.1007/s12265-022-10275-4. Epub 2022 Jun 1.

Abstract

Atherosclerosis is a chronic inflammatory disease that poses a huge economic burden due to its extremely poor prognosis. Therefore, it is necessary to explore potential mechanisms to improve the prevention and treatment of atherosclerosis. A disintegrin and metalloprotease 17 (ADAM17) is a cell membrane-bound protein that performs a range of functions through membrane protein shedding and intracellular signaling. ADAM17-mediated inflammation has been identified to be an important contributor to atherosclerosis; however, the specific relationship between its multiple regulatory roles and the pathogenesis of atherosclerosis remains unclear. Here, we reviewed the activation, function, and regulation of ADAM17, described in detail the role of ADAM17-mediated inflammatory damage in atherosclerosis, and discussed several controversial points. We hope that these insights into ADAM17 biology will lead to rational management of atherosclerosis. ADAM17 promotes vascular inflammation in endothelial cells, smooth muscle cells, and macrophages, and regulates the occurrence and development of atherosclerosis.

Keywords: A disintegrin and metalloprotease 17; Atherosclerosis; Inflammation; Vascular biology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM17 Protein / metabolism
  • Atherosclerosis* / metabolism
  • Endothelial Cells* / metabolism
  • Humans
  • Inflammation / metabolism
  • Membrane Proteins
  • Myocytes, Smooth Muscle / metabolism
  • Signal Transduction

Substances

  • ADAM17 Protein
  • Membrane Proteins
  • ADAM17 protein, human